PharmaShots Weekly Snapshots (January 09 - 13, 2023)

Share this

PharmaShots Weekly Snapshots (January 09 - 13, 2023)

Ono Entered into an Option and Research Collaboration Agreement with Monash University to Discover Anti-GPCR Antibodies

Date: Jan 13, 2023 | Tags: Ono, Monash University, Anti-GPCR Antibodies, Autoimmune, Inflammatory Diseases, Biotech

Penumbra Launches Lightning Flash Thrombectomy System for Blood Clot Removal

Date: Jan 13, 2023 | Tags: Penumbra, Lightning Flash Thrombectomy System, Blood Clot, venous thrombus, pulmonary emboli, Regulatory, MedTech

MediciNova Reports the Completion of Patient Enrollment in the P-II Clinical Trial of MN-166 (ibudilast) for Glioblastoma

Date: Jan 13, 2023 | Tags: Medicinova, MN-166, ibudilast, Glioblastoma, Clinical Trial, P-II

Harbour BioMed Receives the US FDA’s IND Clearance of HBM1020 for the Treatment of Advanced Solid Tumors

Date: Jan 13, 2023 | Tags: Harbour Biomed, HBM1020, Advanced Solid Tumors, Regulatory, US, FDA, IND,

CNS Pharmaceuticals Initiates P-Ib/II Trial of Berubicin for the Treatment of Central Nervous System Lymphoma

Date: Jan 13, 2023 | Tags: CNS Pharmaceuticals, Berubicin, Central Nervous System Lymphoma, Clinical Trial, P-Ib/II Trial

Daiichi Sankyo and AstraZeneca Receive Health Canada’s Approval of Enhertu (trastuzumab deruxtecan) for HER2-Low Metastatic Breast Cancer

Date: Jan 13, 2023 | Tags: Daiichi Sankyo, AstraZeneca, Enhertu, trastuzumab deruxtecan, HER2-Low Metastatic Breast Cancer, Regulatory, Health Canada, Approval

Roche’s Xofluza (baloxavir marboxil) Receives EC’s Approval for the Treatment of Influenza in Children Aged ≥1 Year

Date: Jan 12, 2023 | Tags: Roche, Xofluza, baloxavir marboxil, Influenza, Regulatory, EC, Approval

Solid Biosciences Entered into a Research Collaboration with Phlox Therapeutics to Develop New Therapies for Rare Cardiac Diseases

Date: Jan 12, 2023 | Tags: Solid Biosciences, New Therapies, Rare Cardiac Diseases, Duchenne, Friedreich’s Ataxia, Pharma

Cardiovascular Systems, Inc. Reports the First Patient Enrollment of Diamondback 360 Peripheral Orbital Atherectomy System in Japan

Date: Jan 12, 2023 | Tags: Cardiovascular System, Diamondback 360© Peripheral OAS, Study, KAIZEN, Japan, Clinical Trial, MedTech

AstraZeneca and Avillion Receive the US FDA’s Approval of Airsupra (PT027) for the Treatment of Asthma

Date: Jan 12, 2023 | Tags: AstraZeneca, Avillion, Airsupra, albuterol, budesonide, Asthma, Regulatory, US FDA, Approval

Takeda’s Exkivity (mobocertinib) Receives NMPA’s Approval for EGFR Exon20 Insertion+ NSCLC

Date: Jan 12, 2023 | Tags: Takeda, xkivity, mobocertinib, EGFR Exon20 Insertion+ NSCLC, Regulatory, NMPA, Approval

BioNTech to Acquire InstaDeep for ~$683M

Date: Jan 12, 2023 | Tags: BioNtech, InstaDeep, ~$683M, Acquire, cancers, infectious diseases, M&A

Innovent Reports the First Patients Dosing of Mazdutide (IBI362) in the P-III Study (DREAMS-2) for Type 2 Diabetes

Date: Jan 11, 2023 | Tags: Innovent, Mazdutide, IBI362, Type 2 Diabetes, Clinical Trial, P-III, DREAMS-2 Study

Alvotech Reports Initiation of Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi and Simponi Aria

Date: Jan 11, 2023 | Tags: Alvotech, AVT05, Simponi, Simponi Aria, osteoporosis, respiratory illnesses, autoimmune diseases, Biosimilar, Clinical Trial

Exelixis Entered into a License Agreement with Ajinomoto Co. to Discover and Develop Novel Antibody-Drug Conjugates for Cancer

Date: Jan 11, 2023 | Tags: Exelixis, Ajinomoto, Antibody-Drug Conjugates, Cancer, Biotech, AJICAP technology

BioArctic Partner Eisai Reports MAA Submission of Leqembi (lecanemab) to the EMA for Early Alzheimer's Disease

Date: Jan 11, 2023 | Tags: BioArctic, Leqembi, lecanemab, Alzheimer's Disease, Regulatory, EMA, MAA

Arthrex’s ACL TightRope Implant Receives the US FDA’s Clearance for Anterior Cruciate Ligament Reconstruction

Date: Jan 11, 2023 | Tags: Arthrex, ACL TightRope Implant, Anterior Cruciate Ligament Reconstruction, Regulatory, MedTech, US, FDA

AbbVie Collaborated with Anima Biotech to Discover and Develop mRNA Biology Modulators

Date: Jan 11, 2023 | Tags: AbbVie, mRNA Biology Modulators, oncology, immunology, Biotech

Astellas Signed an Exclusive License and Development Agreement with Selecta Biosciences for Xork IgG Protease

Date: Jan 10, 2023 | Tags: Astellas, Selecta Biosciences, AT845, Xork IgG Protease, Pompe disease, Pharma

Ipsen to Acquire Albireo for ~$952M

Date: Jan 10, 2023 | Tags: Ipsen, Albireo, Bylvay, cholestatic liver diseases, progressive familial intrahepatic cholestasis, Acquire, ~$952M, M&A

Lydus Medical’s Vesseal Device Receives the US FDA’s Clearance for Small Arteries

Date: Jan 10, 2023 | Tags: Lydus Medical, Vesseal Device, Small Arteries, Regulatory, MedTech, US, FDA

Genentech Bio Signed a Discovery Collaboration with Kronos Bio to Advance Novel Therapies Against Transcriptional Targets in Oncology

Date: Jan 10, 2023 | Tags: Genentech, Kronos Bio, Novel Therapies, Oncology, Biotech

Arrowhead and Takeda Report P-II Study (SEQUOIA) of Fazirsiran for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Date: Jan 10, 2023 | Tags: ArFazirsiran, Alpha-1 Antitrypsin Deficiency-Associated Liver Disease, Clinical Trial, P-II, SEQUOIA Study

Neurocrine and Voyager Collaborated to Develop Multiple Gene Therapies for the Treatment of Neurological Diseases

Date: Jan 10, 2023 | Tags: Neurocrine, Voyager, Gene Therapies, Neurological Diseases, Biotech

AstraZeneca to Acquire CinCor Pharma for ~$1.8B

Date: Jan 09, 2023 | Tags: AstraZeneca, Cincor Pharma, baxdrostat, CIN-107, hypertension, M&A, ~$1.8B

Chiesi to Acquire Amryt Pharma for ~$1.48B

Date: Jan 09, 2023 | Tags: Cheisi, Amryt Pharma, epidemolysis bullosa, rare diseases, ~$1.48B, M&A

Phathom Reports P-III Study (PHALCON-NERD-301) Results of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease

Date: Jan 09, 2023 | Tags: Phathom, Vonoprazan, Symptomatic Non-Erosive Gastroesophageal Reflux Disease, Clinical Trial, P-III, PHALCON-NERD-301 Study

Eisai and Biogen Receive the US FDA’s Accelerated Approval of Leqembi (lecanemab-irmb) for Alzheimer's Disease

Date: Jan 09, 2023 | Tags: Eisai, Biogen, Leqembi, lecanemab-irmb, Alzheimer's Disease, Regulatory, US, FDA, Accelerated Approval, Regulatory

CymaBay Entered into a Collaboration and License Agreement with Kaken to Develop and Commercialize Seladelpar for Primary Biliary Cholangitis in Japan

Date: Jan 09, 2023 | Tags: CymaBay, Kaken, Seladelpar, Primary Biliary Cholangitis, Japan, Pharma

Moderna Entered into a Collaboration and License Agreement with Cytomx to Develop mRNA-Based Conditionally Activated Therapies

Date: Jan 09, 2023 | Tags: Moderna, Cytomx, mRNA-Based Therapies, Oncology, Biotech

Related Post: PharmaShots Weekly Snapshots (January 02 - 06, 2023)

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions